Cholesterol lowering in the elderly population

Archives of Internal Medicine

Volumn 159, Issue 15, 1999, Pages 1670-1678

  Grundy, Scott M ^b   Cleeman, James I ^a   Rifkind, Basil M ^b   Kuller, Lewis H ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AGE; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; GERIATRIC CARE; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PATIENT SELECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SECONDARY PREVENTION;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CLINICAL TRIALS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; PATIENT SELECTION; RISK FACTORS; SEX FACTORS; UNITED STATES;

EID: 0033598081     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.15.1670     Document Type: Article

References (64)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.
2. National Center for Health Statistics. Total serum cholesterol levels of adults 20-74 years of age: United States, 1976-80. Vital Health Stat 2. 1986;No.236.
3. Castelli WP, Wilson WF, Levy D, Anderson, K. Cardiovascular risk factors in the elderly. Am J Cardiol. 1989;63:12H-19H.
4. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994;272:1335-1340.
5. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. Arch Intern Med. 1993;153:1065-1073.
6. Zimetbaum P, Frishman WH, Ooi WL, et al. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly: the Bronx aging study. Arterioscler Thromb. 1992;12:416-423.
7. Kannel WB, Castelli WP, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study Ann Intern Med. 1971;74:1-12.
8. Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med. 1990;113:916-920.
9. Benfante R, Reed W. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA. 1990;263:393-396.
10. Barrett-Conner E, Suarez L, Khaw K, Criqui MH, Wingard DL. Ischemic heart disease risk factors after age 50. J Chronic Dis. 1984;37:903-908.
11. Agner E, Hansen PF. Fasting serum cholesterol and triglycerides in a ten-year prospective study in old age, Acta Med Scand. 1983;214:33-41.
12. Siegel D, Kuller L, Lazarus NB, et al. Predictors of cardiovascular events and mortality in the Systolic Hypertension in the Elderly Program pilot Project. Am J Epidemiol. 1987;126:385-399.
13. Harris T, Cook EF, Kannel WB, Goldman, L, Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. J Am Geriatr Soc. 1988;36:1023-1028
14. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Predicting coronary heart disease in middle-aged and older persons. JAMA. 1977;238: 497-499.
15. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women: review of an NHLBI Workshop. Ann Epidemiol. 1992; 2:161-176.
16. Corti M-C, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274:539-544.
17. Frost PH, Davis BR, Burlando A, et al, for the Systolic Hypertension in the Elderly Research Program. Serum lipids and incidence of coronary heart disease: findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation. 1996; 94:2381-2388.
18. Malenka DJ, Baron JA Cholesterol and coronary heart disease: the importance of patient-specific attributable risk. Arch intern Med. 1988;148:2247-2252.
19. Strong JP, McGill HC Jr. The natural history of coronary atherosclerosis, Am J Pathol. 1962;40:37-49.
20. PDAY Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research group. JAMA. 1990;264:3018-3024.
21. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
22. Constantinides P. Plaque hemorrhages, their genesis and their role in supraplaque thrombosis and atherogenesis. In: Glagov S, Newman WP, Schaffter SA, eds. Pathobiology of the Human Atherosclerotic Plaque. New York, NY: Springer-Verlag; 1990:393-411.
23. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl II):II-38-II-46.
24. Kuller L. Borhani N, Furberg C, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the cardiovascular health study. Am J Epidemiol. 1994; 139:1164-1179.
25. Rossouw JE, Lewis B, Rilkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323:1112-1119.
26. Treasure CB, Klein L, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
27. Anderson TJ. Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493
28. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383-1389.
29. Sacks FM. Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
30. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovacular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
31. Pedersen TR, Kjekshus J, Pyorala K, et al. Effects of simvastatin on survival and coronary morbidity in coronary heart disease patients 65 or older [abstract] Circulation. 1995;92(suppl I):672.
32. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) Trial. Ann Intern Med. 1998;129;681-689.
33. Pedersen TR, Olsson AG, Faergeman O, et al, for the Scandinavian Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1436-1439.
34. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998;97:1446-1452.
35. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation. 1998;97:1436-1439.
36. Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on risk reduction. Circulation. 1997;95:1683-1685.
37. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796-1802.
38. Yusuf S, Anand S. Cost of prevention: the case of lipid lowering. Circulation. 1996;93:1774-1776.
39. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease: Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997;336:332-336.
40. National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. Circulation. 1991; 83:2154-2232.
41. Committee of Principal Investigators, World Health Organization. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet. 1980;2:379-385.
42. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results, I: reduction in the incidence of coronary heart disease, JAMA. 1984;251:351-364.
43. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
44. Frick MH, Elo MO, Haapa K, Helsinki Heart Study: primary prevention trial with gemfibrozil in middleaged men with dyslipidemia. N Engl J Med. 1987; 317:1237-1245.
45. Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM. ed. Lowering Cholesterol in High-Risk Individuals and Populations. New York, NY: Marcel Dekker Inc: 1995:33-47.
46. Gordon DJ. Cholesterol and mortality: what can meta-analysis tell us. In: Gallo LL, ed. Cardiovascular Disease 2. New York, NY. Plenum Press. 1995:333-340.
47. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
48. Caro J, Klittich W, McGuire A, et al International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS Eur Heart J. 1999;20:263-268.
49. Downs JR, Clearfield M, Weis S. for the AFCAPS/ TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels JAMA. 1998;279:1615-1622.
50. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med. 1996;124:515-517.
51. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
52. Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcome of smoking cessation in older men and women from coronary artery disease: results from the CASS registry, N Engl J Med. 1988;319:1365-1369.
53. Kuller LH. Future in lipid and lipoprotein research: from preventing clinical disease to preventing elevated risk factors. Atherosclerosis. 1994;108(suppl):S143-S156.
54. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA. 1993;270:487-489.
55. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events Ann Intern Med. 1998; 128:262-269.
56. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and medial thickness as a risk factor for myocardial infarction and stroke in older adults, N Engl J Med. 1999;340:14-22.
57. Arad Y, Spadara LA, Goodman K, et al. Predictive value of electron beam computed tomography of the coronary arteries: 19-month follow-up of 1173 asymptomatic subjects. Circulation. 1996;93:1951-1953.
58. Guerci AD, Spadaro LA, Goodman KJ, et al. Comparison of electron beam computed tomography scanning and conventional risk factor assessment for the prediction of angiographic coronary artery disease. J Am Coll Cardiol. 1998;32:673-679.
59. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21:179-182.
60. Denke MA, Grundy SM. Hypercholesterolemia in the elderly: resolving the treatment dilemma. Ann Intern Med. 1990;112:780-792.
61. Jacobs D, Blackburn H, Higgins M, et al, for Participants in the Conference on Low Cholesterol: Mortality Associations. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation. 1992;86:1046-1060.
62. Stamler J, Stamler R, Brown V, et al. Serum cholesterol: doing the right thing Circulation. 1993; 88:1954-1960.
63. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
64. The Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1995;273:199-208.